June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Expansion of Schlemm’s Canal by Travoprost in Healthy Subjects determined by Fourier-Domain Optical Coherence Tomography
Author Affiliations & Notes
  • JUNYI CHEN
    Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Haili Huang
    Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Shenghai Zhang
    Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Xueli Chen
    Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
  • Xinghuai Sun
    Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai, China
    State Key Laboratory of Medical Neurobiology, Institutes of Brain Science, Fudan University, Shanghai, China
  • Footnotes
    Commercial Relationships JUNYI CHEN, None; Haili Huang, None; Shenghai Zhang, None; Xueli Chen, None; Xinghuai Sun, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1978. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      JUNYI CHEN, Haili Huang, Shenghai Zhang, Xueli Chen, Xinghuai Sun; Expansion of Schlemm’s Canal by Travoprost in Healthy Subjects determined by Fourier-Domain Optical Coherence Tomography. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1978.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the effect of travoprost 0.004% on Schlemm’s canal (SC) in healthy human eyes using Fourier-domain optical coherence tomography (FD-OCT).

Methods: Twelve healthy volunteers were recruited for a double-blind, placebo-controlled, randomized, and paired comparison study. Right eyes of subjects were randomly assigned to receive either travoprost 0.004% or placebo; the contralateral eye received the other treatment. FD-OCT imaging of SC and measurements of intraocular pressure (IOP) were carried out beforeand at 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72 and 84 hours after eye drop instillation.

Results: After instillation of travoprost eye drops, IOP gradually reduced, and the SC lumens expanded, while those values remained unchanged in placebo treated eyes. At 8 hours after the travoprost administration, the mean SC area increased 90.30% and 90.20%, respectively, in nasal and temporal quadrant of the treated eyes as compared to the placebo group. The SC area and IOP showed a similar pattern of changes at most time points examined. In travoprost-treated eyes, a statistically significant correlation between SC area and IOP is observed (r= -0.2817; p=0.0004). Measurements of the SC area showed sufficient repeatability and reproducibility.

Conclusions: SC can be noninvasively imaged and quantitatively assessed in the living healthy human eye by FD-OCT. Travoprost treatment leads to SC lumen expansion accompanied by a drop of IOP in the healthy eye, likely as a result of the enhancement of pressure sensitive trabecular meshwork outflow induced by travoprost.

Keywords: 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 427 aqueous • 568 intraocular pressure  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×